Share Twitter LinkedIn Facebook Email Junne Kamihara, MD, PhD of Dana-Farber Cancer Institute gives an overview of her presentation, TP53 Mutation Carriers: Cancer Genetics in Survivorship Care, which was presented at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read